Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Background Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of
treatment to prevent thrombotic complications of acute coronary syndromes and …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

Background Stent thrombosis is a safety concern associated with use of drug-eluting stents.
Little is known about occurrence of stent thrombosis more than 1 year after implantation of …

Coronary artery stents revolutionized the practice of interventional cardiology after they were
first introduced in the mid-1980s. Since then, there have been significant developments in …

Background—The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in
clopidogrel metabolization. A recently explored CYP2C19* 17 allelic variant has been linked …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Background—Both clopidogrel and prasugrel require biotransformation to active metabolites
by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of …

Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …